INSULINGA CHIDAMLILIK FONIDA SPIRTLI ICHIMLIKLAR BILAN BOG‘LIQ BO‘LMAGAN JIGAR YOG‘LANISHI KASALLIGI BOR BEMORLARDA 2-TUR NATRIY-GLUKOZA KOTRANSPORTYOR INHIBITORLARINING SAMARADORLIGI
##article.subject##:
Non-alcoholic fatty liver disease, steatosis, Dapagliflozin, SGLT2 inhibitors##article.abstract##
Kirish: Spirtli ichimliklar bilan bog‘liq bo‘lmagan jigar yog‘lanishi kasalligi (SIBBJYK) ning rivojlanishi, undan kelib chiqadigan insulinga chidamlilik va keyinchalik 2-tur qandli diabetning paydo bo‘lishi semizlikka chalingan bemorlar uchun davolash taktikasi, davomiyligi va SIBBJYK ning prognoziga ta’sir qiluvchi muhim omillardandir. So‘nggi ma’lumotlarga ko‘ra, natriy-glukoz ko’taruvchi oqsil-2 (SGLT2) ingibitorlari insonlarda spirtli ichimliklar bilan bog‘liq bo‘lmagan steatogepatitning rivojlanishini sekinlashtiradi hamda 2-tur diabet va semizlikka chalingan bemorlarda jigar steatozini yaxshilaydi.
Maqsad: Insulinga chidamlilik fonida NAJBPga chalingan bemorlarda SGLT2 ingibitorlarining samaradorligini baholash.
Materiallar va usullar: 20-65 yosh oralig‘idagi 30 nafar spirtli ichimliklar bilan bog‘liq bo‘lmagan jigar yog‘lanishi tashxisi qo‘yilgan bemorlarga 3 oy davomida har kuni 10 mg dapagliflozin preparati qo‘llanildi. SIBBJYK tashxisi abdominal UTT orqali tasdiqlandi. Barcha bemorlarga davolashdan oldin va keyin biokimyoviy va antropometrik tekshiruvlar, bioimpedansometriya, abdominal UTT o‘tkazildi hamda solishtirma tahlillar amalga oshirildi.
Tadqiqot natijalari: Bemorlarning o‘rtacha yoshi 44,3±8,2 yoshni tashkil etdi. 30 bemordan 18 nafari erkak, 12 nafari ayol edi. Solishtirma tahlillar natijasida jigar shikastlanishining biokimyoviy ko‘rsatkichlari (ALT, GGT), insulin darajasi va insulinga chidamlilik indeksi sezilarli darajada kamaygani kuzatildi. Bioimpedansometriya ko‘rsatkichlari (umumiy yog‘, visseral yog‘) yaxshilandi. Tana vazni indeksi sezilarli darajada pasaydi: davolash boshlanishida o‘rtacha 31,05±3,44 bo‘lgan bo‘lsa, davolashdan so‘ng 28,9±2,34 gacha kamaydi (p<0,05).
Xulosa: Tadqiqotimiz natijalari SGLT2 ingibitorlarining SIBBJYK ga chalingan, ammo qandli diabeti bo‘lmagan bemorlarda potensial samaradorligini ko‘rsatdi. Dapagliflozin terapiyasi fonida biokimyoviy ko‘rsatkichlar, insulinga sezuvchanlik, lipid profili, tana tarkibi va tana vazni sezilarli darajada yaxshilandi.
Библиографические ссылки
Cotter, T. G., & Rinella, M. (2020). Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 158(7), 1851–1864. https://doi.org/10.1053/j.gastro.2020.01.052
Mamasolievna, J. N. ANTIDIABETIC DRUGS IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: A LITERATURE REVIEW. Gospodarka i Innowacje., 2024, 48, 6-13.
Agababyan R. Irina, Djabbarova M. Nafisa. Current issues in modern treatment of nonalcoholic fatty liver disease // Journal of Biomedicine and Practice. 2024, vol. 9, issue 2, pp.44-54
Агабабян И.Р., Хохлачева Д.С., Ким Г.С., Хохлачева Н.А. Изучение компонентного состава организма на ранней стадии неалкогольной жировой болезни печени. Рецепт, 2024, том 27, № 1, 120-126. https://doi.org/10.34883/PI.2024.27.1.007
Targher, G., Tilg, H., & Byrne, C. D. (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The lancet. Gastroenterology & hepatology, 6(7), 578–588. https://doi.org/10.1016/S2468-1253(21)00020-0
Ribeiro Dos Santos, L., & Baer Filho, R. (2020). Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. Metabolism open, 5, 100028. https://doi.org/10.1016/j.metop.2020.100028
Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017). Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Current therapeutic research, clinical and experimental, 87, 13–19. https://doi.org/10.1016/j.curtheres.2017.07.002
Gameil, M.A., Abdelgawad, M., Bahgat, M.H., Elsebaie, A.H., & Marzouk, R.E. (2020). Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. The Egyptian Journal of Internal Medicine, 32.
Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2. PMID: 30178600.
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018). Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia, 61(10), 2155–2163. https://doi.org/10.1007/s00125-018-4702-3
Eriksson, J. W., Lundkvist, P., Jansson, P. A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G. B., Risérus, U., Lind, L., & Oscarsson, J. (2018). Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia, 61(9), 1923–1934. https://doi.org/10.1007/s00125-018-4675-2
Das, C., Tripathy, D., Swain, S., Sudhakaran, N., Uthansingh, K., Mallick, P., & Pati, G. K. (2021). Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. Cureus, 13(5), e14974. https://doi.org/10.7759/cureus.14974
